Positive News Sentiment NASDAQ:NLTX Neoleukin Therapeutics - NLTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.60 +0.02 (+3.48%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.58▼$0.6050-Day Range$0.41▼$0.6152-Week Range$0.38▼$3.84Volume42,115 shsAverage Volume133,816 shsMarket Capitalization$25.34 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Neoleukin Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside916.4% Upside$6.00 Price TargetShort InterestHealthy0.70% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.04) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.71 out of 5 starsMedical Sector75th out of 1,055 stocksPharmaceutical Preparations Industry25th out of 518 stocks 4.0 Analyst's Opinion Consensus RatingNeoleukin Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Neoleukin Therapeutics has a forecasted upside of 916.4% from its current price of $0.59.Amount of Analyst CoverageNeoleukin Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.70% of the float of Neoleukin Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeoleukin Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neoleukin Therapeutics has recently decreased by 14.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeoleukin Therapeutics does not currently pay a dividend.Dividend GrowthNeoleukin Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NLTX. Previous Next 3.3 News and Social Media Coverage News SentimentNeoleukin Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Neoleukin Therapeutics this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neoleukin Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.76% of the stock of Neoleukin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.97% of the stock of Neoleukin Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Neoleukin Therapeutics are expected to grow in the coming year, from ($1.04) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neoleukin Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neoleukin Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoleukin Therapeutics has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Neoleukin Therapeutics (NASDAQ:NLTX) StockNeoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.Read More Receive NLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NLTX Stock News HeadlinesDecember 12, 2022 | finance.yahoo.comNeoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual MeetingNovember 16, 2022 | finance.yahoo.comNeoleukin (NLTX) Stops Development of Lead Drug, Stock DownJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…November 15, 2022 | markets.businessinsider.comMizuho Securities downgrades Neoleukin Therapeutics (NLTX) to a HoldNovember 15, 2022 | finance.yahoo.comNeoleukin Pauses Development Of NL-201, Cuts 40% Of Employee StrengthNovember 15, 2022 | seekingalpha.comNeoleukin cut to Hold at Stifel on plans to drop lead assetNovember 15, 2022 | markets.businessinsider.com5 Analysts Have This to Say About Neoleukin TherapeuticsNovember 15, 2022 | finance.yahoo.comNeoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate UpdateJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 3, 2022 | finance.yahoo.comNeoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual MeetingOctober 1, 2022 | finance.yahoo.comWe're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn RateAugust 10, 2022 | seekingalpha.comNeoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2022 Results - Earnings Call TranscriptAugust 10, 2022 | seekingalpha.comNeoleukin Therapeutics, Inc. 2022 Q2 - Results - Earnings Call PresentationAugust 9, 2022 | msn.comRecap: Neoleukin Therapeutics Q2 EarningsAugust 9, 2022 | finance.yahoo.comNeoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate UpdateAugust 3, 2022 | finance.yahoo.comNeoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth ConferenceJuly 27, 2022 | finance.yahoo.comNeoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022July 4, 2022 | finance.yahoo.comNeoleukin Therapeutics, Inc. (NASDAQ:NLTX) insider upped their holding by 6.7% earlier this yearMay 16, 2022 | finance.yahoo.comNeoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)May 9, 2022 | seekingalpha.comNeoleukin Therapeutics GAAP EPS of -$0.28 beats by $0.02May 9, 2022 | finance.yahoo.comNeoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate UpdateApril 13, 2022 | seekingalpha.comNeoleukin announces preclinical data for immunotherapy candidate NL-201, shares fallApril 13, 2022 | finance.yahoo.comNeoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual MeetingApril 7, 2022 | finance.yahoo.comNeoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology ConferenceMarch 15, 2022 | finance.yahoo.comNeoleukin Therapeutics Announces Appointment of Donna Cochener as General CounselMarch 8, 2022 | finance.yahoo.comNeoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual MeetingMarch 1, 2022 | benzinga.comRecap: Neoleukin Therapeutics Q4 EarningsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NLTX Company Calendar Last Earnings11/14/2022Today1/31/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NLTX CUSIPN/A CIK1404644 Webwww.neoleukin.com Phone(866) 245-0312Fax778-331-4486Employees91Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+908.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,690,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.87% Return on Assets-41.17% Debt Debt-to-Equity RatioN/A Current Ratio10.63 Quick Ratio10.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.37 per share Price / Book0.18Miscellaneous Outstanding Shares42,580,000Free Float36,721,000Market Cap$25.34 million OptionableOptionable Beta1.11 Key ExecutivesJonathan G. DrachmanPresident, Chief Executive Officer, CFO & DirectorPriti PatelChief Medical OfficerBill ArthurHead-Research & Vice PresidentCarl WalkeySenior Vice President-Corporate DevelopmentSean SmithChief Accounting OfficerKey CompetitorsLannettNYSE:LCIAridis PharmaceuticalsNASDAQ:ARDSVincerx PharmaNASDAQ:VINCAprea TherapeuticsNASDAQ:APRECyclerion TherapeuticsNASDAQ:CYCNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 97,319 shares on 11/15/2022Ownership: 2.409%Two Sigma Investments LPBought 30,663 shares on 11/15/2022Ownership: 0.806%Point72 Asset Management L.P.Bought 626,805 shares on 11/14/2022Ownership: 4.848%Renaissance Technologies LLCSold 172,193 shares on 11/14/2022Ownership: 3.387%Sean Michael SmithSold 1,655 sharesTotal: $1,638.45 ($0.99/share)View All Insider TransactionsView All Institutional Transactions NLTX Stock - Frequently Asked Questions Should I buy or sell Neoleukin Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neoleukin Therapeutics in the last year. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NLTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NLTX, but not buy additional shares or sell existing shares. View NLTX analyst ratings or view top-rated stocks. What is Neoleukin Therapeutics' stock price forecast for 2023? 8 analysts have issued 1-year target prices for Neoleukin Therapeutics' stock. Their NLTX share price forecasts range from $2.00 to $10.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 900.0% from the stock's current price. View analysts price targets for NLTX or view top-rated stocks among Wall Street analysts. How have NLTX shares performed in 2023? Neoleukin Therapeutics' stock was trading at $0.5090 on January 1st, 2023. Since then, NLTX shares have increased by 17.9% and is now trading at $0.60. View the best growth stocks for 2023 here. When is Neoleukin Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our NLTX earnings forecast. How were Neoleukin Therapeutics' earnings last quarter? Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.08. What other stocks do shareholders of Neoleukin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), Raytheon Technologies (RTX), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and Home Depot (HD). What is Neoleukin Therapeutics' stock symbol? Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol "NLTX." Who are Neoleukin Therapeutics' major shareholders? Neoleukin Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, Carl Walkey, Jonathan G Drachman, Priti Patel, Redmile Group, Llc, Robert Ho and Sean Michael Smith. View institutional ownership trends. How do I buy shares of Neoleukin Therapeutics? Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neoleukin Therapeutics' stock price today? One share of NLTX stock can currently be purchased for approximately $0.60. How much money does Neoleukin Therapeutics make? Neoleukin Therapeutics (NASDAQ:NLTX) has a market capitalization of $25.55 million. The company earns $-60,690,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis. How can I contact Neoleukin Therapeutics? Neoleukin Therapeutics' mailing address is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. The official website for the company is www.neoleukin.com. The company can be reached via phone at (866) 245-0312, via email at investors@neoleukin.com, or via fax at 778-331-4486. This page (NASDAQ:NLTX) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.